- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 213/643 - Phénoxy-2 pyridinesLeurs dérivés
Détention brevets de la classe C07D 213/643
Brevets de cette classe: 173
Historique des publications depuis 10 ans
|
11
|
6
|
7
|
9
|
10
|
10
|
4
|
13
|
8
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4648 |
6 |
| Board of Regents, The University of Texas System | 5884 |
6 |
| Autifony Therapeutics Limited | 49 |
5 |
| Pharmakea, Inc. | 36 |
5 |
| XENIOPRO GmbH | 15 |
5 |
| Purdue Pharma L.P. | 502 |
4 |
| University of Kansas | 887 |
4 |
| Bayer AG | 3364 |
3 |
| Italfarmaco SpA | 148 |
3 |
| Glaxo Group Limited | 4130 |
2 |
| Bristol-myers Squibb Company | 4850 |
2 |
| General Electric Company | 13859 |
2 |
| BASF SE | 21039 |
2 |
| Centre National de La Recherche Scientifique | 10576 |
2 |
| Bayer Pharma AG | 1054 |
2 |
| The General Hospital Corporation | 4781 |
2 |
| President and Fellows of Harvard College | 6005 |
2 |
| Takeda Pharmaceutical Company Limited | 2706 |
2 |
| Vertex Pharmaceuticals Incorporated | 1626 |
2 |
| Arizona Board of Regents Acting for and on Behalf of Arizona State University | 98 |
2 |
| Autres propriétaires | 110 |